Market Overview

Bank of America Initiates Coverage on Jazz Pharmaceuticals Positive Outlook

Related JAZZ
Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs
JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition'

In a report published Monday, Bank of America initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $74 price objective.

Bank of America reported that, “We initiated coverage of Jazz with a Buy rating and $74 PO, which is based on a sum-of-the-parts DCF analysis and does not require multiple expansion. We like Jazz's focus on areas with strong growth potential and franchise durability, and we expect strong sales and EPS growth over the next several years driven by Xyrem and Erwinaze.”

Jazz Pharmaceuticals closed at $56.03 on Monday.

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings

 

Most Popular

Related Articles (JAZZ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters